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The aspartyl proteinase (PR) encoded by the feline immunodeficiency virus (FIV) was prepared by total chemical synthesis.
The 116-amino-acid polypeptide chain was assembled in a stepwise fashion using a Boc chemistry solid-phase peptide
synthesis approach and subsequently folded into the biologically active dimeric proteinase. The synthetic enzyme showed
proteolytic activity against a variety of different peptide substrates corresponding to putative cleavage sites of the Gag and
Gag–Pol polyproteins of FIV. A comparative study with the proteinase of human immunodeficiency virus type 1 (HIV-1)
showed that the FIV and HIV-1 enzymes have related but distinct substrate specificities. In particular, HIV-1 PR and FIV PR
each show a strong preference for their own MA/CA substrates, despite identical amino acid residues at four of seven
positions from P3– P4* of the substrate including an identical MA/CA cleavage site (between Tyr  Pro residues). FIV PR
also showed a requirement for a longer peptide substrate than HIV-1 PR. Defining the similarities and the differences in
the properties of these two retroviral enzymes will have a significant impact on structure-based drug design. q 1996 Academic
Press, Inc.
INTRODUCTION Thus, disruption of PR function is an excellent target for
the design of protease-specific antiviral agents. Indeed,
Retroviruses are important disease-causing agents in
the HIV-1-encoded protease (HIV-1 PR) (Kramer et al.,
man and animals. Most notable is the human immunode-
1986) is one of most important current targets for struc-
ficiency virus (HIV-1), which causes acquired immunode-
ture-based drug design (Huff, 1991), with the aim of de-
ficiency syndrome (AIDS) in humans (Ratner et al., 1985).
veloping potential therapeutics for AIDS. We have pre-
Feline immunodeficiency virus (FIV) infection is wide-
viously defined the sites of the FIV PR-catalyzed cleav-
spread in domestic and wild cat populations and has
ages that lead to processing of the FIV Gag and Gag–Pol
been shown to induce an AIDS-like syndrome, with pro-
polyproteins to give the structural proteins and enzymes,
gression and severity similar to AIDS in humans (Ackley
including the protease which is involved in virus matura-
et al., 1990; Barlough et al., 1991; Dow et al., 1990; Ishida
tion and infection (Elder et al., 1993).
et al., 1989; Pedersen et al., 1987; Yamamoto et al., 1988,
In the present study, we describe the total chemical
1989, 1991). Molecular studies of FIV have defined the
synthesis of FIV PR, and the determination of its enzy-
sequence and organization of the viral genome and de-
matic activities. The results of this initial investigation of
termined that FIV was a lentivirus, similar in genetic orga-
the comparative enzymatic properties of the FIV PR and
nization to HIV-1 (Elder et al., 1993; Olmstead et al., 1989;
HIV-1 PR indicate differences in specificity for the two
Phillips et al., 1990; Talbott et al., 1989). Because of the
PRs and in substrate length requirements. Such compari-
similarity of the two viruses and associated diseases at
sons facilitate the refining of our understanding of how
the molecular level, the study of FIV is potentially im-
the viral PRs function and may suggest avenues to the
portant for the understanding of HIV and for therapeutic
development of more effective PR inhibitors.
intervention in AIDS.
Retroviruses encode a protease (PR) involved in viral
MATERIALS AND METHODSmaturation (Crawford et al., 1985; Katoh et al., 1985; Ash-
orn et al., 1990) that is essential for viral infectivity (Katoh
Peptide synthesis
et al., 1985; Kohl et al., 1988; Baboonian et al., 1991).
Machine-assisted stepwise solid phase syntheses
were carried out on a 0.2 mmol scale using Boc chemis-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (619) 784-2750. E-mail: jelder@scripps.edu. try in situ neutralization protocols as previously de-
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scribed (Schno¨lzer et al., 1992a). Synthesis of the 116- Assay of enzymatic activity
residue FIV PR polypeptide chain was carried out on
Assays were carried out at 377 in 0.05 M sodium ci-a Boc-Met-OCH2-Pam resin (Applied Biosystems, Foster
trate/0.1 M sodium phosphate buffer, pH 5.25, containingCity, CA). Peptide substrates were synthesized manually
0.1 mM EDTA, 1 mM DTT, and 1 M NaCl. The peptideon 4-MeBHA resin (Peninsula Laboratories Inc., Belmont,
substrates were dissolved in DMSO at a concentrationCA) and were acetylated at their N-terminus with a solu-
of 20 mg/ml, diluted 20-fold into assay buffer, and thention of 20% acetic anhydride/5% DIEA in DMF for 10 min.
1:1 into the reaction mixture. The final concentration ofProduct peptide resins were deprotected and the free
substrates in the reaction mixture was 0.5 mg/ml. For apeptides were released from the resin by cleavage with
20-ml assay, 2 ml of the above enzyme solution was used.HF as previously described (Schno¨lzer et al., 1992a). The
The progress of the cleavage reaction was followed bycrude peptides were precipitated and washed with ice-
reverse-phase HPLC on a Vydac C18 column (0.46 1 15cold diethyl ether, dissolved in 20–70% aqueous acetic
cm) at a flow rate of 1 ml/min using a linear gradientacid, diluted with H2O, and lyophilized.
from 0 to 40% acetonitrile in 0.1% aqueous TFA over 15
min. Cleavage products were collected from analyticalCharacterization of synthetic peptides
HPLC runs based on their absorbance at 214 nm and
Crude peptide products were analyzed by reverse- directly analyzed by electrospray mass spectrometry
phase HPLC using a Vydac C18 column (0.46 1 15 cm) without further manipulation.
at a flow of 1 ml/min with a linear gradient from 0.1% Effect of salt concentration. Standard cleavage assays
aqueous TFA to 65% acetonitrile/35% water containing with the 21-residue MA/CA peptide substrate were car-
0.1% TFA. Sample absorbance was recorded at 214 nm. ried out at NaCl concentrations from 0 to 5 M. Quantita-
Semipreparative HPLC was carried out on a Vydac C4 tion of cleavage products after an incubation time of 1
column (1.0 1 25 cm) using linear solvent gradients on hr at 377 was based on integration of peak areas ob-
a Waters Delta Prep 4000 HPLC system. Solvents A and tained by analytical HPLC.
B were as described above. The concentration of buffer pH dependence. Assays (10 ml) were carried out at
B in A was linearly increased at a rate of 1% per minute different pH using 5 mg of the 21-residue MA/CA peptide
at a flow rate of 3 ml/min. Absorbance was recorded at substrate and 1 ml PR solution. The pH was varied in
220 nm. steps of 0.5 pH units by mixing different amounts of 0.1
Peptide products, both crude and purified, were also M sodium citrate/0.2 M Na2HPO4 buffers containing 0.1
characterized by electrospray mass spectrometry (Model mM EDTA and 1 mM DTT. Quantitation of product forma-
API III, Sciex, Thornhill, Ontario, Canada). Peptides were tion after a 20-min incubation time was done by HPLC
dissolved in either 50% acetic acid or 50% water/acetoni- as described above.
trile/0.1% TFA to a concentration of 1 mg/ml. Samples Measurement of kinetic parameters. Vmax and Km for
were introduced into the atmospheric pressure ionization the cleavage of the 21-residue MA/CA peptide substrate
(API) source of the mass spectrometer by direct infusion were calculated from plots of 1/velocity versus 1/[sub-
using a syringe pump (Harvard Instruments, Boston, MA) strate]. Standard assay conditions were used with sub-
at 5 ml/min as previously described (Schno¨lzer et al., strate concentrations between 5 and 150 mM. Initial ve-
1992b). Data were acquired onto an Apple Macintosh IIfx locities were determined from cleavage product forma-
computer and were processed using the data analysis tion analyzed by reverse-phase HPLC. Assays were set
program MacSpec 3.11b25 (Sciex). Molecular masses up so that less than 20% of the substrate was cleaved.
were calculated from the multiply charged ions using the Inhibition by pepstatin A. Cleavage assays were per-
HyperMass program (MacSpec 3.11b25). formed in the absence of NaCl using otherwise standard
conditions. Pepstatin A concentrations were 1, 5, 10, 50,
Folding of FIV PR and 100 mM, respectively. Quantitation of the cleavage
reaction was as described above.Crude lyophilized FIV PR monomer (8 mg) was dis-
solved in 8 M urea, 0.1 M Na phosphate, pH 5.5, 1 mM
RESULTSDTT to a concentration of 2 mg/ml and dialyzed at 47
against 500-ml batches of buffer containing 0.1 M sodium FIV PR amino acid sequence
acetate, pH 5.5, 0.1 M NaCl, 0.1 mM EDTA, 0.5 mM DTT,
20% glycerol, and varying amounts of urea. The concen- The FIV PR is released from the region of the gag –
pol translation product corresponding to the N-terminaltration of urea in the dialysis buffer was reduced in each
batch from 4, to 2, 1, 0.5, 0.25 M, and then no urea. The domain of the Pol polyprotein (Talbott et al., 1989). We
have previously defined the proteolytic processing sitesresulting turbid solution (16 ml) was centrifuged and
the supernatant concentrated in P3 Centricon tubes to at the N-terminus of the PR and RT regions of the pol
open reading frame (Elder et al., 1993). In conjunction2 ml. The final enzyme solution was adjusted to 30%
glycerol and stored at 0207C. with the translated cDNA sequence, these data define
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Enzymatic activities
Specificity. Aliquots of the solution containing the
folded synthetic FIV PR were assayed for the ability to
FIG. 1. The amino acid sequence of the FIV protease (FIV PR). cleave a synthetic peptide substrate corresponding to
The N-terminus was established by Edman degradation of the PR the the matrix and capsid proteins cleavage site (MA/
purified from virus. The C-terminus was inferred from N-terminal
CA) of the gag translation product (Fig. 2). The sequencesequence analysis of FIV reverse transcriptase, adjacent to the PR
of the substrate was (R)KEEGPPQAY PIQTVNGPQY(R).toward the 3* end of the Pol open reading frame. The predicted
The N- and C-terminal Arg residues were added to im-mass from the 116-amino-acid residue sequence shown is in agree-
ment with the observed mass of the PR present in viral preparations prove the solubility of the peptide in the assay buffers.
[Observed: 13,235 { 2 Da; calculated: 13,234 Da (average isotope Specific cleavage products were observed. Mass spec-
composition)] (Elder et al., 1993).
trometry on the collected fractions corresponding to the
two products showed that cleavage occurred between
the Tyr and Pro residues. This corresponds to the MA/
the 116-residue PR monomer amino acid sequence (Fig.
CA cleavage site observed during viral maturation in vivo
1). Direct HPLC–mass spectrometry of the proteins from
(Elder et al., 1993).
disrupted FIV virions identified a component in the ex-
Synthetic peptide substrates corresponding to all the
pected amount (i.e., in an amount comparable to other proteolytic processing sites of the FIV Gag and Gag–Pol
similarly sized components of the virus pol-encoded en- polyprotein translation products were similarly examined
zyme cassette, and in a much smaller amount than the (Table 1). Specific cleavage was observed in each case,
gag-derived structural proteins), with a mass in exact and for those substrates where the processing sites
agreement with the sequence shown in Fig. 1 (Elder et were known from studies of the viral proteins (Elder et al.,
al., 1993). 1993), there was precise correlation between the studies
with synthetic enzyme on synthetic substrate and the
processing events in vivo. These results demonstrateFIV PR chemical synthesis
that the synthetic FIV PR enzyme has specificity consis-
tent with that required for viral maturation.The 116-amino-acid-residue PR was prepared by total
Kinetics. The rate of FIV PR activity was measuredchemical synthesis using highly optimized stepwise
using an HPLC assay, with the synthetic peptide analogsolid-phase methods (Schno¨lzer et al., 1992a). Synthesis
of the MA/CA cleavage site as substrate (Fig. 2). Enzy-started with the C-terminal Met residue, linked to a cross-
matic activity was enhanced at increasing concentra-linked polystyrene resin support. Chain assembly pro-
tions of NaCl; the maximum rate was obtained at 1.5ceeded in stepwise fashion from the C-terminal to the
M NaCl. This effect of salt concentration is similar to thatamino-terminal residue, as described under Materials
observed for the HIV-1 PR (Wondrak et al., 1991). Theand Methods. The machine-assisted synthesis pro-
effect of pH on activity was also measured, at constantceeded at a rate of 75 residues per day, for a total of
just over 1.5 days. Colorimetric assay for residual free
amine (Sarin et al., 1981) showed that all amino acid
additions had proceeded with 99.7% yield. After com-
pletion of the assembly of the protected peptide chain,
the DNP protecting group was removed from the His
side chain of the resin-bound peptide, the Na-Boc was
removed, and then the remainder of the protecting
groups were removed and the peptide was simultane-
ously cleaved from the resin support, by treatment with
HF plus scavenger.
The crude peptide product was examined by analytical
reverse-phase HPLC and by electrospray mass spec-
trometry. Material of the target MW was observed (Found:
13,235 { 2 Da; calculated: 13,234.4 Da (average isotope
composition)). Purification was performed by semiprep- FIG. 2. Specific cleavage of a synthetic peptide corresponding to the
arative reverse-phase HPLC, using electrospray mass matrix–capsid junction in the FIV Gag open reading frame. The MA/
CA substrate had sequence (R)KEEGPPQAY  EPIQTVNGPQY(R). Thespectrometry to identify fractions containing the desired
N- and C-terminal Arg residues were added to improve solubility ofproduct in large proportion. The combined fractions were
the peptide in the assay buffers. Mass spectrometry on the two prod-
lyophilized, and the partially purified product was folded ucts showed that cleavage occurred between the Tyr and Pro residues.
by dialysis from 8 M urea into native buffer conditions to This corresponds to the same site of processing observed in viral
maturation in vivo. (Elder et al., 1993).give partially purified, folded FIV PR.
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TABLE 1
FIV PR Cleavage of Synthetic Peptides Corresponding to in Vivo Processing Sites of the FIV Gag and Gag–Pol Polyproteins
Cleavage site Sequence Proteolytic activity
P4 P3 P2 P1 P*1 P*2 P*3 P*4
MA/CA R K E E G P P Q A Y  P I Q T V N G V P Q Y R /
R P Q A Y  P I Q T R /
P Q A Y  P I Q T /
R Q A Y  P I Q R {
Q A Y  P I Q 0
CA/NC 1 Y K M Q L  L A E A L T K /
M Q L  L A E 0
CA/NC 2 T K V Q  V V Q S K G S
NC/PR R R G E T I G F V N  Y N K V G R R /
PR/RT R I R L V M  A Q I S D K R /
RT/RNase H R R G A E T W  Y I D G G R K /
RNase H/DU R R C Q T M  M I I E R R
DU/IN Y G S T G V F  S S W V D R I E E A /
ionic strength. Under the conditions used, the enzyme products were determined in all cases by electrospray
was saturated with substrate. Maximum enzymatic activ- mass spectrometry. Comparative measurements on
ity was observed in the range of pH 5–6. Again, this is HIV-1 PR with HIV-1 synthetic peptide substrates were
similar to the pH of maximum activity observed for the also performed. Some of the results are shown in Figs.
HIV-1 PR, under comparable conditions (Hyland et al., 4 and 5 and Table 2.
1991a). In the comparative activity studies of the two retrovi-
Kinetic parameters were determined on the same ral enzymes, two clear-cut results stand out: (i) FIV PR
MA/CA peptide substrate (Fig. 2). Measurements of will not cut an acetyl-(6-residue peptide)amide,
initial rate as a function of substrate concentration whereas HIV-1 PR will cut the corresponding HIV 6-
were performed by HPLC assay. Only the expected residue substrate (Kent, unpublished results; Wlo-
cleavage at the Tyr  Pro site was observed. Typical dawer et al., 1989); FIV PR does, however, specifically
saturation kinetics were observed (Fig. 3a). A double cut an acetyl-(8-residue peptide)amide (Table 2). Thus
reciprocal plot (Fig. 3b) of the data gave Km 10 mM there are significant differences in the substrate
for the synthetic peptide analogue of the FIV MA/CA length requirement for the two enzymes. (ii) Although
cleavage site. This Km is considerably higher than the both enzymes cut their corresponding Gag MA/CA
high micromolar to millimolar Km values reported for cleavage sites between Tyr and Pro residues, the FIV
the HIV-1 PR on unmodified peptide substrate ana- PR and HIV-1 PR show a strong preference for their
logues of the HIV-1 MA/CA processing site (Hyland et own MA/CA Tyr  Pro substrates, despite four identi-
al., 1991b; Ido et al., 1991; Griffiths et al., 1992). The cal amino acids in the P3 – P3* positions (see Fig. 4).
observed Vmax was similar to that of HIV-1 PR acting HIV-1 PR cuts the FIV MA/CA Tyr  Pro site approxi-
on the analogous HIV-1 substrate. This Vmax measure- mately 50 times slower than the FIV PR does (Fig. 4a).
ment is only approximate, because protein concentra- FIV PR cuts the HIV-1 MA/CA Tyr  Pro site approxi-
tion measurements for FIV PR have not yet been cali- mately 200 times slower than HIV-1 PR cuts the same
brated. However, Km values are unaffected by concen- substrate (Fig. 4b). The small difference in reciprocal
tration of active enzyme. Further comparative studies, rates may be due to uncertainties in determining the
now under way, will clarify this point. concentration of active enzyme present in each case.
It is interesting to note that FIV PR cleaves a syn-
Substrate specificity—comparison with HIV-1 PR
thetic peptide spanning the NC/PR processing site
[sequence Ac-Arg1-Arg-Ile-Gly4-Phe5-Val-Asn7  Tyr8-In addition to the determination of processing sites
Asn-Lys-Val-Gly-Arg-Argramide; italicized residuesin the viral Gag – Pol polyprotein described above, a
added for solubility] at the expected Asn7  Tyr8, andvariety of studies of the specificity of FIV PR were
also between the Gly4  Phe5 residues. An additionalcarried out on synthetic peptide substrates. Assays
were analyzed by HPLC and identities of the cleavage cleavage site has been fortuitously created by the use
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HIV-1 PR cleaved the FIV CA/NC No. 1 peptide between
the Leu  Ala and Leu  Leu peptide bonds (Fig. 5 and
Table 2). This vividly demonstrates the similarities and
differences in the specificity of the two enzymes on pep-
tide substrates.
CONCLUSIONS
The FIV PR represents an important addition to the
family of well-characterized retroviral proteases (Miller
et al., 1989a,b). As our understanding of the FIV PR in-
creases, it will be important to relate that knowledge to
the existing database for HIV-1 PR. The two enzymes
have related activities, but at the same time we have
defined critical differences, the most important being the
observation that HIV-1 PR and FIV PR each show a strong
preference for their own MA/CA substrates, despite an
identical 0Tyr  Pro0 cleavage site in each case and
substantially similar neighboring sequences. This type
of subtle distinction in enzymatic properties makes the
comparative study of the properties of FIV PR in the con-
text of the HIV-1 PR an important model system for struc-
ture-based drug design. Further study will be facilitated
by the recent completion of the crystal structure of FIV
PR (Dunn et al., 1995).
Currently, HIV-1 PR inhibitors show promise as effec-
tive AIDS therapeutics (Huff, 1991; Mitsuya et al., 1990;
Vacca et al., 1994), although the development of PR inhib-
itor-resistant strains of HIV-1 has been reported from
clinical trials (Otto et al., 1993; El-Farrash et al., 1994).
This is not unexpected, since the HIV-1 reverse tran-
scriptase has a high error rate that leads to rapid muta-
tion of viral proteins subject to selective pressure. How-
ever, it does point to the utility of designing PR inhibitors
which demonstrate inhibition against closely related PRs
(i.e., HIV-1 and FIV) in that they may be better able to
inhibit mutant forms of the PRs.
The observation that FIV PR requires a substrate 8
FIG. 3. Initial velocity kinetic measurements at 377C, pH 5.25, [NaCl] amino acids in length is important in that many PR inhibi- 1 M, of the cleavage by FIV PR of the synthetic MA/CA substrate
tors for HIV-1 PR are based on peptides less than 7described in the legend to Fig. 2. (a) Velocity versus (substrate concen-
amino acids in length. In requiring a longer substrate,tration) showed saturation as is typical of enzyme-catalyzed reactions;
(b) a double reciprocal plot of 1/velocity versus 1/[substrate]. Observed the FIV PR is in effect being more specific in needing
Km  10 mM. the S4 through S4* substrate binding pockets to be filled.
Inhibitors based on an 8-amino-acid peptide may be
more effective against FIV PR, as well as HIV-1 PR and
of the N-terminal Arg residues to enhance solubility. mutant PRs. Initial results with pyrrolidine-containing a-
A longer natural substrate sequence [Ac-Arg-Arg-Gly- keto amide-based inhibitors (Slee et al., 1995) support
Glu-Thr-Ile-Gly-Phe-Val-Asn  Tyr-Asn-Lys-Val-Gly- this conclusion for FIV PR since addition of FIV-specific
Arg-Argramide] did not display this phenomenon and amino acid residues to the primary core structure (Slee et
was specifically processed only at the expected Asn- al., 1995) increases the specificity for FIV PR dramatically
Tyr cleavage site (Elder et al., 1993). (Wong, personal communication).
In addition, with the CA/NC No. 1 cleavage site, the The results from the FIV and HIV-1 MA/CA cleavage
enzymes exhibit somewhat different specificities: the FIV site are interesting in that they indicate the importance
PR cuts the CA/NC No. 1 peptide between Leu  Leu of the P2 and P3* positions in the recognition and cleav-
residues, while the HIV-1 PR cuts the corresponding HIV- age of the peptide by the FIV and HIV-1 PRs. Incorpora-
tion of amino acid side chains at these positions, re-1 substrate between Leu  Ala residues. However, the
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FIG. 4. Action of FIV PR and HIV-1 PR on synthetic peptide analogues of the MA/CA Tyr  Pro processing site in the FIV and HIV-1 Gag translation
products. Note the strong preference of each retroviral enzyme for the substrate from the same virus. (a) FIV substrate Ac-RPQAY-PIQTR-NH2 (top)
treated for 16 hr with FIV PR (middle) or HIV-1 PR (bottom). (b) HIV-1 substrate Ac-RSQNY-PIVQR-NH2 (top) treated for 16 hr with FIV PR (middle)
or HIV-1 PR (bottom). The digestions were analyzed by HPLC and the hydrolysis products identified by electrospray mass spectrometry. Reduced
and oxidized forms of DTT are marked.
sulting in a peptide that is cleaved equally by both PRs, By exploiting the similarities and differences in sub-
strate specificity between the FIV and HIV-1 PRs, in con-may facilitate the development of peptide-based inhibi-
tors that are equally effective for FIV PR and HIV-1 PR. junction with the three-dimensional structures, it may be
FIG. 5. Action of FIV PR and HIV-1 PR on a synthetic peptide analogue of the FIV first (5*-most) capsid/nucleocapsid processing site. The FIV
PR cuts the substrate at only one site, corresponding to the 0Leu  Leu0 processing site observed in vivo. The HIV-1 PR cuts the same 0Leu
 Leu0 site and also the neighboring 0Leu  Ala0 peptide bond, at similar rates. (In HIV-1, the CA/NC#1 processing event occurs at a 0Leu
 Ala0 site in the analogous HIV-1 Gag sequence). (Left) FIV PR; (Right) HIV-1 PR.
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TABLE 2
Substrate Length Requirements for FIV PR and HIV-1 PR
Activity detected
FIV HIV
Cleavage site Peptide sequencea PR PR
MA/CA R K K K G P P Q A Y  P I Q T V N G V P Q Y Yes Yes
8-mer P Q A Y  P I Q T Yes Yes
6-mer Q A Y  P I Q No Yes
CA/NC 1 Y K M Q L  L A E A L T K Yes Yesb
6-mer M Q L  L A E No Yes
a All substrates were Acetyl-Peptide-amides. Activities were observed by reverse phase HPLC.
b HIV-1 PR cuts equally at Leu5  Leu6 and at Leu6  Ala7.
tion of proteolytic processing sites within the Gag and Pol polypro-possible to design PR inhibitors which are highly specific
teins of feline immunodeficiency virus. J. Virol. 67, 1869–1876.for retroviral PRs and resistant to mutations in the PR
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